AKBA - Akebia Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
AKBA price evolution
AKBA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.5 | $41.96 | $42.92 | |
| Short term investments | ||||
| Net receivables | $32.17 | $29.77 | $26.62 | $39.29 |
| Inventory | $20.49 | $23.87 | $25.53 | $15.69 |
| Total current assets | $100.12 | $112.1 | $112.94 | $118.15 |
| Long term investments | ||||
| Property, plant & equipment | $11.83 | $13.26 | $14.66 | $16.05 |
| Goodwill & intangible assets | $77.06 | $86.08 | $95.09 | |
| Total noncurrent assets | $108.1 | $112.53 | $123.55 | |
| Total investments | ||||
| Total assets | $207.14 | $220.2 | $225.48 | $241.7 |
| Current liabilities | ||||
| Accounts payable | $13.49 | $10.11 | $11.88 | $14.63 |
| Deferred revenue | $83.31 | $83.92 | $83.39 | |
| Short long term debt | $17.5 | |||
| Total current liabilities | $65.71 | $107.3 | $66.49 | $99.87 |
| Long term debt | $38.35 | $44.33 | $37.78 | $26.13 |
| Total noncurrent liabilities | $146.65 | $186.25 | $172.42 | |
| Total debt | $44.33 | $37.78 | $43.63 | |
| Total liabilities | $257.54 | $253.95 | $252.74 | $272.29 |
| Shareholders' equity | ||||
| Retained earnings | -$1655.56 | -$1635.52 | -$1626.93 | -$1608.95 |
| Other shareholder equity | $0.01 | $0.01 | $0.01 | $0.01 |
| Total shareholder equity | -$33.75 | -$27.26 | -$30.58 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $42.92 | $90.47 | $149.8 | $228.7 |
| Short term investments | $39.99 | |||
| Net receivables | $39.29 | $39.18 | $50.88 | $26.9 |
| Inventory | $15.69 | $21.76 | $38.2 | $61 |
| Total current assets | $118.15 | $184.95 | $272.01 | $371.4 |
| Long term investments | ||||
| Property, plant & equipment | $16.05 | $34.37 | $40.61 | $35.5 |
| Goodwill & intangible assets | $95.09 | $127.14 | $163.18 | $199.22 |
| Total noncurrent assets | $123.55 | $166.88 | $253.54 | $272.7 |
| Total investments | $39.99 | |||
| Total assets | $241.7 | $351.83 | $525.55 | $644.1 |
| Current liabilities | ||||
| Accounts payable | $14.63 | $18.02 | $33.59 | $41.3 |
| Deferred revenue | $83.39 | $88.03 | $42.38 | $40.56 |
| Short long term debt | $17.5 | $32 | $97.54 | |
| Total current liabilities | $99.87 | $124.76 | $256.49 | $187.1 |
| Long term debt | $26.13 | $34.08 | $33.7 | $96.4 |
| Total noncurrent liabilities | $172.42 | $217.73 | $192.6 | $209.38 |
| Total debt | $43.63 | $95.04 | $131.25 | $121 |
| Total liabilities | $272.29 | $342.49 | $449.09 | $396.5 |
| Shareholders' equity | ||||
| Retained earnings | -$1608.95 | -$1552.91 | -$1460.35 | -$1177.5 |
| Other shareholder equity | $0.01 | $0.01 | $0.01 | $0.01 |
| Total shareholder equity | -$30.58 | $9.34 | $76.46 | $247.62 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $37.43 | $43.65 | $32.61 | $56.2 |
| Cost of revenue | $17.05 | $11.61 | $18.66 | |
| Gross Profit | $32.81 | $26.6 | $21 | $37.53 |
| Operating activities | ||||
| Research & development | $7.65 | $9.73 | $9.87 | |
| Selling, general & administrative | $26.92 | $25.44 | $25.44 | |
| Total operating expenses | $44.01 | $34.56 | $35.23 | $32.92 |
| Operating income | -$7.96 | -$14.22 | $4.61 | |
| Income from continuing operations | ||||
| EBIT | -$6.43 | -$15.49 | $2.03 | |
| Income tax expense | ||||
| Interest expense | -$6.66 | $2.15 | $2.5 | $1.42 |
| Net income | ||||
| Net income | -$20.04 | -$8.58 | -$17.98 | $0.61 |
| Income (for common shares) | -$8.58 | -$17.98 | $0.61 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $194.62 | $292.6 | $213.58 | $295.31 |
| Cost of revenue | $74.15 | $84.8 | $153.39 | $295.91 |
| Gross Profit | $120.47 | $207.81 | $60.18 | -$0.6 |
| Operating activities | ||||
| Research & development | $63.08 | $129.11 | $147.85 | $218.49 |
| Selling, general & administrative | $100.23 | $138.7 | $174.16 | $153.95 |
| Total operating expenses | $163.49 | $286.92 | $325.5 | $375.84 |
| Operating income | -$43.02 | -$79.11 | -$265.32 | -$376.44 |
| Income from continuing operations | ||||
| EBIT | -$45.89 | -$76.88 | -$262.9 | -$374.59 |
| Income tax expense | ||||
| Interest expense | $6.03 | $15.69 | $19.94 | $8.87 |
| Net income | ||||
| Net income | -$51.92 | -$92.56 | -$282.84 | -$383.46 |
| Income (for common shares) | -$51.92 | -$92.56 | -$282.84 | -$383.46 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$8.58 | -$17.98 | $0.61 | |
| Operating activities | ||||
| Depreciation | $10.45 | $10.39 | $14.84 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.07 | $2.36 | $1.51 | |
| Total cash flows from operations | -$10.07 | -$19.43 | -$2.31 | |
| Investing activities | ||||
| Capital expenditures | -$0.03 | |||
| Investments | ||||
| Total cash flows from investing | -$0.03 | -$0.03 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $18.95 | $6.71 | |
| Net borrowings | $7.63 | $0.27 | -$8 | |
| Total cash flows from financing | $27.34 | $7.64 | $18.48 | -$1.29 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$8.89 | -$2.46 | -$0.96 | -$3.6 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$51.92 | -$92.56 | -$282.84 | -$383.46 |
| Operating activities | ||||
| Depreciation | $41.85 | $35.28 | $36.13 | $31.55 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.32 | $17.85 | $22.73 | $24.46 |
| Total cash flows from operations | -$23.38 | -$73.15 | -$252.97 | -$110.39 |
| Investing activities | ||||
| Capital expenditures | -$0.11 | -$0.06 | -$0.32 | |
| Investments | $40 | -$39.69 | ||
| Total cash flows from investing | -$0.11 | $39.94 | -$40 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.79 | $7.6 | $88.95 | $211.75 |
| Net borrowings | -$32 | -$33 | $19.98 | |
| Total cash flows from financing | -$25.21 | $14.6 | $133.73 | $231.72 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$48.59 | -$58.67 | -$79.29 | $81.33 |
News
Fundamentals
| Market cap | $408.28M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 211.54M |
| Revenue | $169.88M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$45.99M |
| Revenue Q/Q | -10.98% |
| Revenue Y/Y | N/A |
| P/E ratio | -8.88 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.40 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.22 |
|---|---|
| ROA | -20.57% |
| ROE | N/A |
| Debt/Equity | -8.90 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.52 |
| Quick ratio | 1.21 |